SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic Sarcoma

NCT07817095 · tracked via the Priya Life Science China tracker

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Phase

Phase 2

Started

2026-09

Last updated

2026-09-14

Condition(s) studied

Undifferentiated Pleomorphic Sarcoma (UPS)

Investigational drug(s) / intervention(s)

ToripalimabLiposomal doxorubicinStereotactic body radiotherapy (SBRT)

Toripalimab: Toripalimab 240 mg IV q3w; 3 neoadjuvant doses from SBRT start; maintenance up to 14 cycles until progression, death, or unacceptable toxicity.

Liposomal doxorubicin: Liposomal doxorubicin 30-40 mg/m2 IV q3w; 2 neoadjuvant cycles. Non-MPR/HPR: 2-4 adjuvant cycles (2 cycles if HPR \>30%).

Stereotactic body radiotherapy (SBRT): SBRT 8-10 Gy x 5 (median 8 Gy x 5), over 5-10 days in weeks 1-3, IGRT required.

Study summary

This is a prospective, single-center, single-arm, open-label phase II exploratory study to evaluate the efficacy, safety, and immune remodeling effects of stereotactic body radiotherapy (SBRT) combined with reduced-dose anthracycline chemotherapy and the PD-1 inhibitor toripalimab as neoadjuvant therapy, followed by postoperative stratified maintenance therapy, in patients with localized high-risk undifferentiated pleomorphic sarcoma (UPS). A Simon two-stage design will be used, with 39 patients planned (stage 1: 13 patients; 35 patients in total, including a 10% dropout rate). Treatment consists of SBRT (8-10 Gy in 5 fractions) followed by toripalimab (240 mg intravenously every 3 weeks, 3 cycles in the neoadjuvant phase) combined with liposomal doxorubicin (30-40 mg/m² intravenously every 3 weeks, 2 cycles in the neoadjuvant phase). After response evaluation, radical surgery is performed. Postoperative stratified maintenance therapy is delivered according to pathological response: patients achieving major pathologic response (MPR) or hyalinized pathologic response (HPR) receive toripalimab monotherapy (240 mg every 3 weeks, up to 14 cycles), while those not achieving MPR/HPR receive toripalimab combined with liposomal doxorubicin (2-4 cycles). The primary endpoint is the rate of major pathologic response (MPR). Secondary endpoints include the rate of hyalinized pathologic response (HPR), radiologic objective response rate (ORR), R0 resection rate, limb salvage rate, and safety.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: Inclusion Criteria: 1. Male or female, aged 18 to 75 years. 2. Histologically confirmed UPS, screened locally and confirmed by central pathology before enrollment. Adequate IHC (at least CK, S100, SOX10, SMA, desmin, MDM2, CDK4) and NGS when feasible (MDM2/CDK4 amplification mandatory) to exclude dedifferentiated liposarcoma and other differentiated tumors. 3. UPS of extremities or trunk. Max diameter \>5 cm, or \<=5 cm with any of: encasement of major neurovascular bundle \>180 degrees; expected limb functional loss \>50% after resection; MDT deems R0 difficult. SBRT-feasible anatomy with \>3 mm margin to critical neurovascular structures or joint. 4. Regional nodes evaluated by imaging (US/CT/MRI/PET-CT). Suspicious nodes (short axis \>=10 mm, abnormal morphology, or high FDG) require pathology. Uninvolved nodes must not be irradiated; involved nodes included with radical dose or resected. 5. Treatment-naive: no prior chemotherapy, targeted therapy, immunotherapy, or local radiotherapy. 6. At least one measurable lesion per RECIST v1.1. 7. ECOG 0-1. 8. Adequate organ function. 9. Signed ICF, good compliance, willing to provide fresh tumor and blood for translational research. Exclusion Criteria: 1. Other malignancy, except completed treatment with no recurrence/metastasis within 2 years. 2. Major surgery within 4 weeks, or systemic steroids (\>10 mg/day prednisone equivalent) or immunosuppressants within 2 weeks. 3. Active infection requiring systemic therapy; active HBV (DNA \>=2000 IU/mL), HCV, syphilis, or HIV positive. 4. Active or relapsing autoimmune disease. 5. Severe comorbidity: NYHA \>=III, ischemic heart disease, uncontrolled hypertension/diabetes; interstitial lung disease or severe pulmonary impairment. 6. Known active brain metastases. 7. Pregnancy/breastfeeding, or refusal of effective contraception. 8. Any investigator-judged risk to safety or completion.

Primary outcome measure(s)

Rate of Major Pathologic Response (MPR) — At surgery

Trial sites (1)

Facility	City	Region	Status
Tianjin Medical University Cancer Institute & Hospital	Tianjin	China

More Tianjin Medical University Cancer Institute and Hospital trials in China

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer Recruiting

Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer Active, not recruiting

A Phase II Exploratory Study of Sacituzumab Tirumotecan Combined With Envafolimab for TROP2-Positive Advanced Biliary Tract Cancers Previously Treated With First-Line Immunotherapy Combined With Chemotherapy. Starting soon

Albumin-bound Paclitaxel (Ⅱ)-Combined Regimens for Pancreatic Cancer Starting soon

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07817095 on ClinicalTrials.gov ↗ ← All trials in China